Perspective Therapeutics, Inc. (CATX) Stock Forecast
CATX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 14 analysts
- Price target
- $12.29 average of analyst targets
- Upside to target
- +466.2% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.24
- 52-week range
- $2.05 – $5.65
CATX analyst ratings
14 analystsNumber of analysts at each rating.
CATX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CATX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.31 | −$0.22 | −$0.35 | +29.9% | 11 |
| Current fiscal year (2026) | −$0.99 | −$1.27 | −$0.83 | −$1.40 | +29.4% | 10 |
| Next fiscal year (2027) | −$1.04 | −$1.30 | −$0.68 | −$0.99 | −4.8% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CATX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $51,790 | $0 | $167,200 | −75.2% | 12 |
| Current fiscal year (2026) | $297,330 | $0 | $1.0M | −66.4% | 15 |
| Next fiscal year (2027) | $296,240 | $0 | $1.0M | −0.4% | 13 |
CATX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CATX revenue: reported and forecast
CATX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.29 | −$0.25 | −$0.25 | −$0.25 | −$0.25 | −16.5% | 6 up · 0 down |
| Current fiscal year (2026) | −$1.12 | −$1.03 | −$0.98 | −$0.98 | −$0.99 | −11.8% | 6 up · 0 down |
| Next fiscal year (2027) | −$1.13 | −$1.10 | −$1.01 | −$1.02 | −$1.04 | −8.3% | 5 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CATX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CATX beat in 5 of 12.
What analysts expect from CATX
14 analysts cover Perspective Therapeutics; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.29, 466.2% above the latest close of $2.17. Analysts expect earnings of −$0.99 per share for 2026, +29.4% from a year earlier. For 2027 the average estimate is −$1.04 per share on revenue of $0.3 million. Perspective Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: CATX income statement, CATX key metrics, CATX chart. See the CATX stock overview for the latest quote and news.
CATX forecast FAQ
What is Perspective Therapeutics's price target?
The average analyst price target for Perspective Therapeutics is $12.29, 466.2% above the latest close of $2.17.
Is Perspective Therapeutics a buy, hold or sell?
Of 14 analysts covering Perspective Therapeutics, 10 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Perspective Therapeutics's EPS forecast?
Analysts forecast −$0.99 per share for 2026 (range −$1.27 to −$0.83); for 2027 the estimate is −$1.04.
What is Perspective Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −66.4%; for 2027 it is $0.3 million.
When does Perspective Therapeutics report earnings?
Perspective Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.24.
Does Perspective Therapeutics usually beat earnings estimates?
Perspective Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.